Cargando…

Association of nonalcoholic fatty liver disease with bone mineral density and serum osteocalcin levels in Korean men

OBJECTIVE: Bone mineral density has been reported to negatively associate with nonalcoholic fatty liver disease. Osteocalcin, a bone formation marker and metabolic regulator, has been previously evaluated as the mediator between bone mineral density and nonalcoholic fatty liver disease. Herein, we a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hae Jin, Shim, Sang Goon, Ma, Bong Oh, Kwak, Ji Yeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2016
Materias:	Original Articles: Metabolic Liver Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739310/ https://www.ncbi.nlm.nih.gov/pubmed/26636404 http://dx.doi.org/10.1097/MEG.0000000000000535

Ejemplares similares

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
por: Hall, Zoe, et al.
Publicado: (2017)

IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
por: Harley, Isaac TW, et al.
Publicado: (2014)

The endothelial function biomarker soluble E‐selectin is associated with nonalcoholic fatty liver disease
por: Simons, Nynke, et al.
Publicado: (2020)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease
por: Flores‐Guerrero, Jose L., et al.
Publicado: (2021)

Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study
por: Loomba, Rohit, et al.
Publicado: (2014)

Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
por: Decaris, Martin L., et al.
Publicado: (2016)

Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
por: Pavlides, Michael, et al.
Publicado: (2017)

Prescription of statins in suspected non‐alcoholic fatty liver disease and high cardiovascular risk, a population‐based study
por: van den Berg, Eline H., et al.
Publicado: (2019)

Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis
por: Traussnigg, Stefan, et al.
Publicado: (2017)

Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice
por: Locatelli, Irene, et al.
Publicado: (2014)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

Serum coding and non‐coding RNAs as biomarkers of NAFLD and fibrosis severity
por: Di Mauro, Stefania, et al.
Publicado: (2019)

Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
por: Loomba, Rohit, et al.
Publicado: (2015)

Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis(1)(2)(3)(4)
por: Chung, Mei, et al.
Publicado: (2014)

Mesenchymal iron deposition is associated with adverse long‐term outcome in non‐alcoholic fatty liver disease
por: Eder, Sebastian K., et al.
Publicado: (2020)

Diagnostic accuracy of fibrosis tests in children with non‐alcoholic fatty liver disease: A systematic review
por: Draijer, Laura G., et al.
Publicado: (2021)

Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice
por: Gariani, Karim, et al.
Publicado: (2015)

Oxidative stress is associated with suspected non‐alcoholic fatty liver disease and all‐cause mortality in the general population
por: Damba, Turtushikh, et al.
Publicado: (2020)

Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008‐2019
por: Sugiyama, Aya, et al.
Publicado: (2021)

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
por: Braude, Michael, et al.
Publicado: (2022)

Metabolic profiling of fatty liver in young and middle‐aged adults: Cross‐sectional and prospective analyses of the Young Finns Study
por: Kaikkonen, Jari E., et al.
Publicado: (2016)

Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial
por: George, Elena S., et al.
Publicado: (2022)

Vertical sleeve gastrectomy activates GPBAR‐1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice
por: Ding, Lili, et al.
Publicado: (2016)

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
por: Mowry, Christopher J., et al.
Publicado: (2021)

Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two‐dimensional shear wave elastography in non‐alcoholic fatty liver disease
por: Mendoza, Yuly P., et al.
Publicado: (2021)

Repeated measurements of non‐invasive fibrosis tests to monitor the progression of non‐alcoholic fatty liver disease: A long‐term follow‐up study
por: Balkhed, Wile, et al.
Publicado: (2022)

Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma
por: Weinfurtner, Kelley, et al.
Publicado: (2020)

Interaction between CHOP and FoxO6 promotes hepatic lipid accumulation
por: Kim, Dae Hyun, et al.
Publicado: (2020)

TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids
por: de Mello, Vanessa D., et al.
Publicado: (2020)

Non-alcoholic fatty liver disease: a practical approach to treatment
por: Dyson, J K, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
por: Dyson, Jessica K, et al.
Publicado: (2014)

Prospective Study to Analyze the Concordance Between a Standardized Visual Method With Pathology to stratify Nonalcoholic Fatty Liver Disease in Cadaveric Liver Grafts Evaluated for Transplantation
por: Sampaio-Neto, José, et al.
Publicado: (2023)

Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease
por: Neilson, Laura Jane, et al.
Publicado: (2021)

Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent
por: De Silva, Sampath, et al.
Publicado: (2018)

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

Apolipoprotein CIII Overexpressing Mice Are Predisposed to Diet-Induced Hepatic Steatosis and Hepatic Insulin Resistance
por: Lee, Hui-Young, et al.
Publicado: (2011)

Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance
por: Kozlitina, Julia, et al.
Publicado: (2011)

Role of Patatin-Like Phospholipase Domain-Containing 3 on Lipid-Induced Hepatic Steatosis and Insulin Resistance in Rats
por: Kumashiro, Naoki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uotdig54jcei654anl00mllenc